Related Experiment Video
Updated: Mar 9, 2026

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies
Mariangela Russo1,2, Alberto Bardelli1,2
1Department of Oncology, University of Torino, 10060 Candiolo (TO), Italy.
Abstract:
Precision oncology relies on targeted drugs, such as kinase inhibitors, that are presently administered based on molecular profiles obtained from surgical or bioptic tissue samples. The inherent ability of human tumors to molecularly evolve in response to drug pressures represents a daunting diagnostic challenge. Circulating free DNA (cfDNA) released from primary and metastatic lesions can be used to draw molecular maps that can be continuously updated to match each tumor's evolution. We will present evidence that liquid biopsies can effectively interrogate how targeted therapies drive lesion-specific drug-resistance mechanisms. The impact of drug-induced molecular heterogeneity on subsequent lines of treatment will also be discussed.
Insights
Liquid biopsies using circulating free DNA (cfDNA) can track tumor evolution and drug resistance. This approach helps personalize cancer treatment by monitoring molecular changes over time.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Precision oncology uses targeted drugs based on tumor molecular profiles from tissue samples.
- Tumor evolution under drug pressure presents a significant diagnostic challenge.
- Monitoring these molecular changes is crucial for effective treatment.
Purpose of the Study:
- To demonstrate the utility of liquid biopsies in tracking tumor evolution.
- To investigate how targeted therapies induce drug resistance mechanisms.
- To understand the impact of molecular heterogeneity on treatment strategies.
Main Methods:
- Analysis of circulating free DNA (cfDNA) from liquid biopsies.
- Continuous molecular profiling of primary and metastatic lesions.
- Interrogation of lesion-specific drug-resistance mechanisms.
Main Results:
- Evidence showing liquid biopsies can effectively map tumor molecular evolution.
- Demonstration of how targeted therapies drive specific resistance mechanisms.
- Assessment of drug-induced molecular heterogeneity's impact on treatment.
Conclusions:
- Liquid biopsies offer a dynamic approach to monitoring cancer treatment response.
- cfDNA analysis enables continuous updates of tumor molecular maps.
- This method aids in adapting subsequent treatment lines based on evolving resistance patterns.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy

